D. E. Shaw & Co., Inc.
- SEC CIK
- 0001009207
- Latest filing
- Aug 14, 2026
RYTM holding history
Rhythm Pharmaceuticals, Inc. in every 13F filed by D. E. Shaw & Co., Inc., including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.
RYTM overviewAll 13F holders of RYTMFull Q2 2026 holdings
- Shares (Q2 2026)
- 30,168
- Value
- $3.35M
- % of portfolio
- <0.1%
- Quarters held
- 16
- Since Q1 2021
| Quarter | Shares | Value | % of portfolio | Share change | Action | All holders |
|---|---|---|---|---|---|---|
| Q2 2026 | 30,168 | $3.35M | <0.1% | −2,484−7.6% | Reduced | Holders |
| Q1 2026 | 32,652 | $2.84M | <0.1% | +1,296+4.1% | Added | Holders |
| Q4 2025 | 31,356 | $3.36M | <0.1% | +27,771+774.6% | Added | Holders |
| Q3 2025 | 3,585 | $362.0K | <0.1% | −20,693−85.2% | Reduced | Holders |
| Q2 2025 | 24,278 | $1.53M | <0.1% | −59,591−71.1% | Reduced | Holders |
| Q1 2025 | 83,869 | $4.44M | <0.1% | +35,671+74.0% | Added | Holders |
| Q4 2024 | 48,198 | $2.70M | <0.1% | +43,904+1,022.4% | Added | Holders |
| Q3 2024 | 4,294 | $225.0K | <0.1% | +4,294 | New | Holders |
| Q2 2024 | 0 | $0 | 0.0% | −10,462−100.0% | Sold out | Holders |
| Q1 2024 | 10,462 | $453.3K | <0.1% | −118,030−91.9% | Reduced | Holders |
| Q4 2023 | 128,492 | $5.91M | <0.1% | +128,492 | New | Holders |
| Q2 2023 | 0 | $0 | 0.0% | −278,203−100.0% | Sold out | Holders |
| Q1 2023 | 278,203 | $4.96M | <0.1% | −77,327−21.7% | Reduced | Holders |
| Q4 2022 | 355,530 | $10.4M | <0.1% | +172,461+94.2% | Added | Holders |
| Q3 2022 | 183,069 | $4.49M | <0.1% | +146,577+401.7% | Added | Holders |
| Q2 2022 | 36,492 | $151.0K | <0.1% | −60,493−62.4% | Reduced | Holders |
| Q1 2022 | 96,985 | $1.12M | <0.1% | +96,985 | New | Holders |
| Q2 2021 | 0 | $0 | 0.0% | −31,653−100.0% | Sold out | Holders |
| Q1 2021 | 31,653 | $673.0K | <0.1% | – | – | Holders |
Livermore's 13F data starts with Q1 2021, so Q1 2021 has no change from the previous quarter.